Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.47 |
| ▸ | DHPS | P49366 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27252002 | 0.80 | HTR2A (0.48) | HTR1ADRD2HTR2APDE4AEIF4EBP1 | |
| SCHEMBL324010 | 0.78 | KMT2A (0.49) | P2RX7PDE4A | |
| SCHEMBL38652062 | 0.78 | KMT2A (0.49) | P2RX7PDE4A | |
| SCHEMBL1757848 | 0.76 | ACHE (0.59) | MAPK14DHPSEGLN1 | |
| SCHEMBL29809414 | 0.76 | ACHE (0.59) | MAPK14DHPSEGLN1 | |
| SCHEMBL14771218 | 0.74 | EGLN1 (0.49) | MAPK14DHPSEGLN1 | |
| Phenanthroline SCHEMBL28483605 | 0.73 | CYP3A4 (0.53) | P2RX7PDE4AEGLN1 | |
| SCHEMBL3963990 | 0.72 | KDM4E (0.48) | PDE4A | |
| SCHEMBL4064849 | 0.72 | PDE4A (0.47) | PDE4AKAT2B | |
| SCHEMBL15815770 | 0.72 | PDE4A (0.47) | DHPSPDE4AKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038812-A1 | CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS | AMGEN INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082358-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | MAPK14 972/4885DHPS 3132/4885P2RX7 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.